1. Pink Sheet

Judge Gorsuch Could Be Pharma Ally In FDA Disputes

 
• By Brenda Sandburg

Supreme Court nominee's opposition to deference for administrative agencies could help biopharma industry in its battle over off-label communications if the issue ever goes before the court; he also supports securities litigation reform.

US-Supreme-Court_V1_1200

Judge Neil Gorsuch's appointment to the Supreme Court would be beneficial to the biopharmaceutical sector given his opposition to giving deference to administrative agencies when laws are ambiguous and his criticism of securities class actions.

Trump nominated Gorsuch to fill the high court's vacancy on Jan. 31. The Senate Judiciary Committee is to begin a hearing on his nomination March 20. Gorsuch was confirmed to the U.S

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.